Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Beguin

Showing results (1-10 of 242) with videos related to

Pageof 25
Sort By:
Haematologica|November 5, 2002
Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patientsYves Beguin
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 19, 2003
Soluble transferrin receptor for the evaluation of erythropoiesis and iron statusYves Beguin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Intravenous iron and recombinant human erythropoietin in cancer patientsYves Beguin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Serum selenium in lymphomaYves Beguin, Georges Weber
Haematologica|April 6, 2006
The place of positron emission tomography imaging in the management of patients with malignant lymphomaGuy Jerusalem, Yves Beguin
Oncology|October 26, 2005
Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon)John Glaspy, Yves Beguin
Expert Opinion on Pharmacotherapy|September 5, 2014
Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areasYves Beguin, Aurélie Jaspers
Expert Opinion on Emerging Drugs|May 14, 2013
Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantationSophie Servais, Yves Beguin, Frédéric Baron
Haematologica|June 13, 2003
Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftmentFrédéric Baron, Pascale Frère, Yves Beguin
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 25, 2011
Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioningSophie Servais, Frédéric Baron, Yves Beguin
Pageof 25

Showing results (1-10 of 242) with videos related to

Sort By:
Pageof 25
Haematologica|November 5, 2002
Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patientsYves Beguin
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 19, 2003
Soluble transferrin receptor for the evaluation of erythropoiesis and iron statusYves Beguin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Intravenous iron and recombinant human erythropoietin in cancer patientsYves Beguin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Serum selenium in lymphomaYves Beguin, Georges Weber
Haematologica|April 6, 2006
The place of positron emission tomography imaging in the management of patients with malignant lymphomaGuy Jerusalem, Yves Beguin
Oncology|October 26, 2005
Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon)John Glaspy, Yves Beguin
Expert Opinion on Pharmacotherapy|September 5, 2014
Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areasYves Beguin, Aurélie Jaspers
Expert Opinion on Emerging Drugs|May 14, 2013
Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantationSophie Servais, Yves Beguin, Frédéric Baron
Haematologica|June 13, 2003
Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftmentFrédéric Baron, Pascale Frère, Yves Beguin
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|February 25, 2011
Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioningSophie Servais, Frédéric Baron, Yves Beguin
Pageof 25